Blueprint Medicines Corporation (BPMC) Expected to Announce Quarterly Sales of $4.32 Million

Lloyd Doyle
December 15, 2017

A number of equities analysts have issued reports on the stock. DA Davidson started coverage on shares of Blueprint Medicines in a report on Friday, September 29th. At the moment, the average analyst rating for BPMC is Moderate Buy. Cowen reissued a "buy" rating on shares of Blueprint Medicines in a research report on Friday, November 10th. Meanwhile, the average 12-month price target from Wall Street analysts is now $79.50, this means that the stock is overpriced by -3.346%. Narrowing our focus to the previous 1 month, the shares have been down by -0.12%. TheStreet cut shares of Blueprint Medicines Corporation from a "c-" rating to a "d+" rating in a research note on Wednesday, May 3rd. The company has analyst rating of 2.20 on scale of 1-5. Blueprint Medicines presently has a consensus rating of "Buy" and a consensus price target of $83.78.

Blueprint Medicines Corporation (NASDAQ BPMC) traded down $6.34 on Tuesday, reaching $81.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28.


In the past 52 weeks the company's stock price has moved within the range of $25.34 to $92.00. In the most recent financial results released by Blueprint Medicines Corporation, for the quarter ending on 2017-09-30, the company posted EPS of -0.96. Return on Equity (ROE) stands at -43.1% and Return on Investment (ROI) of -33.4 percent. The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $6.02 million. The share last price represents downtick move of -10.70% in value from company's 52-Week high price and shows 224.23% above change in value from its 52-Week low price. The firm's revenue was up 31.0% compared to the same quarter past year.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BPMC. The company's a year ago sales total was 7690. Following the sale, the insider now owns 18,334 shares of the company's stock, valued at $1,199,960.30. American International Group Inc. increased its stake in Blueprint Medicines by 8.1% in the third quarter. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. Russell Investments Group Ltd. raised its position in Blueprint Medicines by 216.7% in the second quarter. Sandia Holdings LLC owned approximately 0.44% of Blueprint Medicines worth $11,971,000 at the end of the most recent reporting period. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company's stock valued at $71,746,000 after purchasing an additional 195,517 shares during the last quarter. The stock was sold at an average price of $70.31, for a total transaction of $2,109,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. However, it could also mean that something is fundamentally wrong with the company. MYL ended at price of $39.53 after 6.08 million shares traded at hands. Most of the active traders and investors are keen to find ways to compare the value of stocks. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,639 shares of company stock worth $4,871,743. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & global copyright & trademark legislation. The original version of this report can be accessed at https://stocknewstimes.com/2017/12/14/fy2018-earnings-forecast-for-blueprint-medicines-corporation-bpmc-issued-by-wedbush.html. TimesSquare Capital Management LLC increased its stake in Blueprint Medicines by 54.9% in the third quarter. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER